Abstract: Annual low dose CT (LDCT) for lung cancer screening (LCS) has been a covered Medicare preventive service since 2015. LCS eligibility criteria are more complex than those for other preventive services, and are likely responsible for low utilization of LCS nationally. Our health care system (The MetroHealth System, Cleveland, OH) has offered LDCTs since 2013 and clinical decision support (CDS) evaluating LCS orders against Medicare eligibility criteria since 2016. Through three versions of CDS, we sought to address established gaps in both generalist and specialist knowledge regarding LCS indications, risks and benefits, reducing ineligible LCS orders while guiding clinicians to the correct imaging study. We review our CDS's evolution, present an evaluation of our CDS's strengths and weaknesses as well as a plan for future development.
Describe the new knowledge and additional skills the participant will gain after attending your presentation.: The attendee will understand the unique nature of lung cancer screening orders and how CDS can benefit clinicans ordering these studies.
Nicholas Riley (Presenter)
The MetroHealth System, Case Western Reserve University
Peter Greco, The MetroHealth System, Case Western Reserve University
Yasir Tarabichi, The MetroHealth System, Case Western Reserve University
David Kaelber, The MetroHealth System, Case Western Reserve University